All the funding deals in the biomarker testing market
Last updated: 13 July 2026
In our updated market reports, you will find everything you need
The biomarker testing market is attracting funding across cancer detection, preventive health, multiomics, microbiome testing, and AI-powered diagnostics.
We conducted deep research and collected 51 biomarker testing market funding deals announced from Q1 2024 through Q2 2026.
We refresh this page very often to add new biomarker testing market funding deals and update existing information.
Insights
- The 51 biomarker testing market funding deals raised about $1.78 billion between Q1 2024 and Q2 2026.
- The five largest biomarker testing market deals represented about 51% of all funding, which shows that capital was concentrated among a small group of companies.
- Function Health raised the largest round in the dataset, with $298 million announced in Q4 2025.
- Freenome, BillionToOne, Alamar Biosciences, and Karius also raised rounds of at least $100 million for biomarker testing technologies.
- The median biomarker testing market deal was $15 million, while 22 of the 51 rounds were below $10 million.
- Cancer detection was one of the strongest funding themes, especially for liquid biopsy, multiomics, proteomics, and blood-based screening companies.
- Preventive health platforms gained investor attention by combining frequent blood testing with software, clinical review, and personalized health insights.
- AI became more visible in the biomarker testing market through digital pathology, virtual staining, biomarker discovery, and image-based cancer diagnosis.
- Alternative sample types are expanding the biomarker testing market beyond standard blood tests. Funded companies are now analyzing urine, breath, sweat, skin, and microbiome samples.
- Funding reached about $899 million in 2024 and $711 million in 2025. The first half of 2026 added about $167 million.
Summary table of the funding deals for the biomarker testing market since 2024
We define the biomarker testing market as tests and analytics that measure biological signals linked to disease, aging, performance, or health risk.
It includes Blood Biomarker Tests, Genomic Biomarkers, Proteomic Biomarkers, Microbiome Testing, Liquid Biopsy Tests, and Inflammation Biomarkers.
It excludes broader adjacent markets unless the product is built specifically for this use case.
We focused exclusively on pure players, defined as companies with at least 70–80% of their business directly tied to the biomarker testing market.
Our analysis has been done at a global level with a minimum funding threshold of $300k.
If you want a longer-term view, we also have a study of how funding activity in the biomarker testing market has changed over the years.
| Name | What they do | Amount in $ | Quarter | Source(s) |
|---|---|---|---|---|
| Acurion | Uses AI to detect cancer biomarkers and support precision oncology. | $4.3M | Q2 2026 | Acurion |
| ViewsML | Creates virtual biomarker stains and discovers biomarkers from pathology images. | $4.9M | Q2 2026 | ViewsML |
| PlaqueTec | Uses intracoronary liquid biopsy to identify causes of cardiovascular inflammation. | $5.0M | Q2 2026 | BusinessWire |
| Moonlight AI | Turns routine blood and cytology images into genomic diagnostic insights. | $3.1M | Q2 2026 | EU-Startups |
| Lucis | Combines blood biomarkers, health data, and AI for preventive care. | $20.0M | Q2 2026 | Lucis |
| ClearNote Health | Develops blood tests for early pancreatic and ovarian cancer detection. | $52.0M | Q2 2026 | ClearNote Health |
| Haga Bioscience | Develops scalable tools for RNA biomarker validation and variant detection. | $2.3M | Q2 2026 | KI Innovations |
| Precede Biosciences | Develops blood-based liquid biopsy tests for precision medicine. | $63.5M | Q1 2026 | Precede Biosciences |
| Cyclomics | Develops sensitive blood cancer tests using circular DNA sequencing. | $2.9M | Q1 2026 | Cyclomics |
| Cancilico | Uses AI to diagnose blood cancers from blood and bone marrow samples. | $2.8M | Q1 2026 | HTGF |
| Emerald | Offers preventive health reviews and comprehensive blood biomarker testing. | $1.8M | Q1 2026 | UK Tech News |
| Biopeak | Uses diagnostics, multiomics, and AI to assess aging and health risks. | $2.7M | Q1 2026 | The Economic Times |
| Spotlight Pathology | Uses AI to improve blood cancer diagnosis from medical images. | $1.8M | Q1 2026 | UK Innovation & Science Seed Fund |
| GlycanAge | Measures biological aging and inflammation through glycan biomarker testing. | $8.7M | Q4 2025 | EU-Startups |
| Decode Age | Provides microbiome and biomarker tests focused on aging and longevity. | $1.7M | Q4 2025 | Entrackr |
| Function Health | Offers direct-to-consumer testing across more than 160 health biomarkers. | $298.0M | Q4 2025 | PRNewswire |
| Beacon Biosignals | Uses EEG data and AI to develop brain health biomarkers. | $86.0M | Q4 2025 | BioSpace |
| Octave Bioscience | Develops blood biomarker tests for multiple sclerosis and neurological diseases. | $35.6M | Q3 2025 | BioSpace |
| Mercy BioAnalytics | Develops liquid biopsy tests for early ovarian and lung cancer detection. | $59.0M | Q3 2025 | Mercy BioAnalytics |
| Molecular You | Measures more than 250 blood biomarkers to predict health risks. | $5.0M | Q3 2025 | Molecular You |
| Portal Biotech | Develops single-molecule protein sequencing for diagnostics and biomarker discovery. | $35.0M | Q2 2025 | NATO Innovation Fund |
| NiaHealth | Offers clinician-supported preventive blood testing across dozens of biomarkers. | $4.2M | Q2 2025 | BetaKit |
| GeneCentric Therapeutics | Develops blood-based genomic tests for precision cancer treatment. | $8.0M | Q2 2025 | GeneCentric |
| PHASE Scientific | Develops urine tests for cancer, women’s health, and infectious diseases. | $34.0M | Q2 2025 | PHASE Scientific |
| SpotitEarly | Develops at-home breath tests for early cancer detection. | $20.3M | Q2 2025 | BusinessWire |
| CND Life Sciences | Uses skin biopsies to detect biomarkers linked to neurodegenerative diseases. | $13.5M | Q2 2025 | CND Life Sciences |
| Superpower | Offers preventive health testing across more than 100 blood biomarkers. | $30.0M | Q2 2025 | Fierce Healthcare |
| Tvaster Genkalp | Develops molecular and liquid biopsy tests for cancer diagnosis. | $1.25M | Q2 2025 | Elets eHealth |
| Epicore Biosystems | Develops sweat sensors that measure hydration and health biomarkers. | $26.0M | Q1 2025 | PRNewswire |
| Owlstone Medical | Develops breath tests for cancer, liver, and digestive diseases. | $27.0M | Q1 2025 | Owlstone Medical |
| Oxford Cancer Analytics | Develops blood tests for early cancer detection using protein biomarkers. | $11.0M | Q1 2025 | Oxford Cancer Analytics |
| Senseera | Develops liquid biopsy tests using cell-free chromatin biomarkers. | $7.1M | Q1 2025 | PRNewswire |
| Proton Intelligence | Develops continuous potassium monitoring for people with kidney disease. | $6.95M | Q4 2024 | BusinessWire |
| OneCell Diagnostics | Develops liquid biopsy tests using tumor cells and molecular biomarkers. | $16M | Q4 2024 | Entrackr |
| MetaSight Diagnostics | Develops multiomics tests for chronic and acute diseases. | $8M | Q4 2024 | BioSpace |
| PrognomiQ | Develops multiomics blood tests for lung cancer and complex diseases. | $34M | Q4 2024 | PrognomiQ |
| Aignostics | Uses AI to find pathology biomarkers and precision medicine insights. | $34M | Q4 2024 | Aignostics |
| Sunbird Bio | Develops blood protein tests for Alzheimer’s and neurological disorders. | $14M | Q4 2024 | BusinessWire |
| MARAbio | Develops a blood test for maternal autoantibody-related autism biomarkers. | $19M | Q4 2024 | Behavioral Health Business |
| Viome | Offers at-home microbiome testing with AI-based health recommendations. | $25M | Q3 2024 | Vator |
| PreciseDx | Uses AI and biomarker data to assess cancer risks. | $20.7M | Q3 2024 | PRNewswire |
| ZOE | Offers microbiome and blood response tests for personalized nutrition. | $15M | Q3 2024 | TechCrunch |
| Function Health | Offers membership-based testing across more than 100 health biomarkers. | $53M | Q2 2024 | MobiHealthNews |
| BillionToOne | Develops molecular tests for prenatal screening and cancer care. | $130M | Q2 2024 | BillionToOne |
| Sova Health | Offers gut microbiome testing and personalized digestive health programs. | $1M | Q2 2024 | Indian Startup News |
| Karius | Provides a blood-based genomic test for infectious diseases. | $100M | Q2 2024 | BusinessWire |
| Biofidelity | Develops genomic biomarker tests for lung cancer treatment decisions. | $24M | Q2 2024 | Biofidelity |
| Tiny Health | Offers at-home gut and vaginal microbiome tests for families. | $8.5M | Q1 2024 | Medical Design & Development |
| Alamar Biosciences | Develops proteomics tools for disease detection and biomarker analysis. | $128M | Q1 2024 | PRNewswire |
| Freenome | Develops blood-based multiomics tests for early cancer detection. | $254M | Q1 2024 | Freenome |
| Circular Genomics | Develops circular RNA tests for psychiatry and neurological care. | $8.3M | Q1 2024 | PRNewswire |
Related blog posts
- The most highly valued startups in the biomarker testing market
- How healthy is startup funding in the biomarker testing market right now?
- The startups that have raised the most funding in the biomarker testing market
- The main fundraising trends in the biomarker testing market
